Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson\'s disease in comparison with other oral non-ergot dopamine agonists. It should be tested whether piribedil is superior to continued pramipexole or ropinirole treatment regarding improvement of reduced vigilance and cognitive performance in patients with Parkinson\'s disease.
Epistemonikos ID: 54a7a36c854bc26365e8e814ebcbe41261dfa51e
First added on: May 05, 2024